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ABSTRACT 
Emulgel have emerged as one of the most interesting topical delivery system as it has dual release control system i.e. gel and emulsion. The 
topical applications of the drug offers the potential advantages of delivering the drug directly to the site of action and delivering the drug for 
extended period of time at the effected site that mainly acts at the related regions. The major objective behind this formulation is enhancing the 
topical delivery of hydrophobic drug (clindamycin phosphate) by formulating clindamycin phosphate emulgel using carbopol 941 as a gelling 
agent. In addition, light liquid paraffin as oil, tween-20 and span-20 as emulsifiers and propylene glycol as co-surfactant were selected for 
preparation of emulgel. Clindamycin phosphate is an antibiotic useful for the treatment of a number of infections. It is of the lincosamide class. 
Clindamycin phosphate is a semi synthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. 
Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. Topical clindamycin phosphate reduces free 
fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes), an anaerobe found in 
sebaceous glands and follicles.  The prepared emulgel were evaluated for their physical appearance, pH determination, viscosity, spreadability, 
extrudability, in vitro drug release, anti acne activity and stability. All the prepared emulgel showed acceptable physical properties, 
homogeneity, consistency, spreadability, viscosity and pH value. The best formulation F4 showed better antiacne activity when compared with 
all formulation.  
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Acne vulgaris is a common dermatological disorder with 
prevalence reported to reach upto 85% of population across 
various regions1. It has a significant impact on the quality of 
life2,3, psychosocial development as well as self-esteem of the 
patients4. It affects areas of the skin having the highest 
population of sebaceous follicles, most common being the 
face, the upper part of chest, and the back5.Until recently 
follicular epidermal hyperproliferation with subsequent 
plugging of the follicles (comedones) was considered to be 
the earliest event in the development of acne and closed 
comedones were regarded as the precursors of inflammatory 
lesions6,7.Current evidence has shown that inflammatory 
events can precede microcomedone formation and that the 
development of follicular duct plugs is also influenced, to 
some degree, by inflammation caused by Propionibacterium 
acnes6, 8,9. P. acnes are an anaerobic organism present in the 
sebaceous glands which contributes to the pathophysiology 
of acne in several ways. It stimulates inflammation by 
producing pro-inflammatory mediators through toll like 
receptor-2 (TLR-2) and activation of the innate immune 
system8-10. Antibiotic treatment against P.acnes is one of the 
essential elements for the treatment of acne vulgaris. Though 
systemic antibiotics have been used for several years to 
reduce the population of P. acnes, topical antibiotics are 
more acceptable because of their fewer side effects and 
interactions. Among the routinely prescribed topical 
antibiotics for acne vulgaris, clindamycin has retained better 
efficacy over a period of time11. Clindamycin also has anti-
inflammatory properties which are likely to contribute to its 
anti-acne therapeutic effects in a significant manner12. 
Concentration of the drug in the pilosebaceous ducts affects 
the efficacy of topical antimicrobial agents. Moreover 
emergence of resistance also correlates with low and 
variable concentrations of the drug achieved in the pilo-
sebaceous ducts13,14. Therefore, reliable drug delivery 
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systems providing better drug penetration can result in 
better efficacy and also help in the prevention of 
development of resistance. When gels and emulsions are 
used in combined form the dosage forms are referred as 
EMULGELS6. Emulgels are also called as creamed gel, quassi 
emulsion, gelled emulsion7. In recent years, there has been 
great interest in the use of novel polymers with complex 
functions as emulsifiers and thickeners because the gelling 
capacity of these compounds allows the formulation of stable 
emulsions and creams by decreasing surface and interfacial 
tension and at the same time increasing the viscosity of the 
aqueous phase8. Emulgels for dermatological use have 
several favorable properties such as being thixotropic, 
greaseless, easily spreadable, easily removable, emollient, 
nonstaining, long shelf life, bio-friendly, transparent and 
pleasing appearance9. The aim of the present study was to 
statistically optimize emulgel for enhanced skin delivery of a 
model drug of anti-acne drug clindamycin phosphate, which 
was effective candidate for the treatment of acne 15-18. 
MATERIALS AND METHODS 
Materials 
  Clindamycin phosphate was kindly provided as a gift sample 
from Cure tech skin formulation Baddi, Himanchal Pradesh, 
India. Spans 20, tween 20 were purchased from SD Fine 
Chemicals Mumbai, India. Carbopol 941 was purchased from 
CDH Laboratories New Delhi, India. Liquid paraffin, 
propylene glycol, methyl parabens and propyl parabens 
extra pure were purchased from Hi-Media laboratories 
Mumbai, India.  Propionibacterium acne was obtained from 
microbial culture collection, national centre for cell science, 
Pune, Maharashtra, India. All other chemicals used were of 




Preparation of carbopol 
Fifty grams of the carbopol gel was prepared by dispersing 
one gram of carbopol powder in 50 ml purified water with 
aid of moderate speed stirrer (50 rpm), and then the pH was 
adjusted to 6.5-6.8 using 0.5 N of sodium hydroxide. 
Preparation of emulsion 
The general method was employed for preparation of an 
emulsion was as follows: The oil phase was prepared by 
dissolving span 20 in liquid paraffin in the different ration 
given in table 1 while the aqueous phase was prepared by 
dissolving tween 20 in purified water as given in table 1. One 
grams of clindamycin was dissolved in 5 ml of ethanol, while 
0.15 g of methylparaben and 0.05 g of propylparaben were 
dissolved in 5 gm of propylene glycol and both were mixed 
with aqueous phase. Both the oily and aqueous phases were 
separately heated to 70-80°C. Then, the oil phase was added 
to the aqueous phase with continuous stirring at 500 rpm 
until cooled to room temperature19.  
Formulation of clindamycin emulgel   
Six formulas of clindamycin were prepared by dispersing the 
obtained emulsions with the gel in 1:1 ratio with gentle 
stirring until get homogenous emulgel. The composition of 
different formulation was given in table 1 
 














F1 500 0.5 5 2 5 5 100 
F2 500 0.5 5 2 10 5 100 
F3 500 1.0 10 4 5 5 100 
F4 500 1.0 10 4 10 5 100 
F5 500 1.5 5 2 5 5 100 
F6 500 1.5 5 2 10 5 100 
 
Determination of λ max of clindamycin 
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
7.4 pH buffer solution in 10 ml of volumetric flask. The 
resulted solution 1000µg/ml and from this solution 1 ml 
pipette out and transfer into 10 ml volumetric flask and 
volume make up with 7.4 pH buffer solution prepare 
suitable dilution to make it to a concentration range of 10-50 
μg/ml. 2 ml of standard solution mix with 1 ml methyl 
orange and extracted with 3 ml of chloroform. Pipette out 
the chloroform layer and take the absorbance against 
chloroform as blank. The spectrum of this solution was run 
in 400-800 nm range in U.V. spectrophotometer (Labindia-
3000+). The spectrum peak point graph of absorbance of 
clindamycin phosphate versus wave length. 
Evaluation of emulgel 
Physical characteristic  
The prepared emulgel formulations were inspected visually 
for their pH, colour, homogeneity, consistency, grittiness, 
texture and phase separation 
 
Determination of pH  
The pH of emulgel formulations was determined by digital 
pH meter. One gram of gel was dissolved in 25 ml of distilled 
water and the electrode was then dipped in to gel 
formulation for 30 min until constant reading obtained.  And 
constant reading was noted. The measurement of pH of each 
formulation was done in triplicate and average values were 
calculated20. 
Washability  
Formulations were applied on the skin and then ease and 
extent of washing with water were checked manually. 
Extrudability study  
The Emulgel formulations were filled into collapsible metal 
tubes or aluminium collapsible tubes. The tubes were 
pressed to extrude the material and the extrudability of the 
formulation was checked21.  
Spreadability  
Two glass slides of standard dimensions (6×2) were 
selected. The emulgel formulation whose spreadability had 
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to be determined was placed over one of the slides. The 
second slide was placed over the slide in such a way that the 
formulation was sandwiched between them across a length 
of 6 cms along the slide. 100 grams of weight was placed up 
on the upper slide so that the emulgel formulation between 
the two slides was traced uniformly to form a thin layer. The 
weight was removed and the excess of the emulgel 
formulation adhering to the slides was scrapped off. The 
lower slide was fixed on the board of the apparatus and one 
end of the upper slide was tied to a string to which 20 gram 
load could be applied with the help of a simple pulley. The 
time taken for the upper slide to travel the distance of 6 cms 
and separate away from lower slide under the direction of 
the weight was noted. The experiment was repeated and the 
average of 6 such determinations was calculated for each 
emulgel formulation22,23. 
 
   Where, S=Spreadability (gcm/sec) 
    m = weight tied to the upper slide (20 grams)   
    l= length of glass slide (6cms).  
   t = time taken is seconds. 
Viscosity  
The measurement of viscosity of the prepared emulgel was 
done using Brookfield digital Viscometer. The viscosity was 
measured using spindle no. 6 at 10 rpm and 250C. The 
sufficient quantity of gel was filled in appropriate wide 
mouth container. The emulgel  was  filled  in  the  wide  
mouth  container in such way that it should  sufficiently  
allow  to  dip  the  spindle of the viscometer. Samples of the 
emulgel were allowed to settle over 30 min at the constant 
temperature (25 ±/10C) before the measurements24.  
In-vitro drug release studies 
The in-vitro diffusion of drug from the different emulgel 
preparations were studied using the classical standard 
cylindrical tube fabricated in the laboratory; a simple 
modification of the cell is a glass tube of 15mm internal 
diameter and 100mm height. The diffusion cell membrane 
was applied with one gram of the formulation and was tied 
securely to one end of the tube, the other end kept open to 
ambient conditions which acted as donor compartment. The 
cell was inverted and immersed slightly in 250 ml of beaker 
containing neutralizing phthalate buffer, freshly prepared 
(pH 5.4) as a receptor base and the system was maintained 
for 2 hrs at 37± 0.5o C. The media was stirred using magnetic 
stirrer. Aliquots, each of 5 ml volume were withdrawn 
periodically at predetermined time interval of up to 12 hrs 
and replaced by an equal volume of the receptor medium. 
The aliquots were suitably diluted with the receptor medium 
and analyzed by UV-Vis spectrophotometer at 486 nm using 
neutralizing phthalate buffer as blank25,26. 
Drug release kinetics study 
The results of in-vitro release profile obtained for all the 
formulations were plotted in kinetic models as follows,  
1.  Cumulative of drug released versus time (zero order 
kinetic model).  
2.  Log cumulative percent drug remaining to be absorbed 
versus time (First order model)  
3. Cumulative amount of drug release versus square root of 
time (Higuchi model)  
4.  Log cumulative drug released versus log time 
(Korsmeyer-Peppas model)27 
Antiacne activity studies 
The prepared emulgel formulations were tested against 
propionibacterium acne strain using well diffusion method. 
Clindamycin used as standard drug. There were 3 
concentration used which are 30, 20 and 10 μg/ml for 
antibiogram studies. The plates were incubated at 37oC for 
24 hr. and then examined for clear zones of inhibition 
around the wells with particular concentration of drug. 
RESULTS AND DISCUSSION 
λ max of clindamycin was found to be 486 nm by using U.V. 
spectrophotometer (Labindia-3000+) in linearity range 10-
50µg/ml Fig.1. Emulgel formulations were white viscous 
creamy preparation with a smooth homogeneous texture 
and glossy appearance. Results have been discussed in table 
2. The results of washability, extrudability and spreadability 
of all formulation were given in table 3. From the result it 
was found that formulation F1-F6 has good washability 
ability, formulation F3, F4 has good Extrudability and 
Spreadability of all formulation was found to in range of 
12.25to14.56. The viscosity of the emulgel was obtained by 
using brookfield digital viscometer. The viscosity of the 
formulations increases as concentration of polymer 
increases and pH of prepared emulgel were measured by 
using pH meter (Orion Research, Inc., USA). The pH of the 
emulgel formulation was in the range of 6.9 to7.05 which 
considered acceptable to avoid the risk of skin irritation 
upon application to skin table 4. Release of drug from 
clindamycin emulgel was significantly slower, which 
confirmed that slight prolonged drug release rate. 
Incorporation of carbomer affected the release rate of the 
drug. By increasing the amount of carbomer, the release rate 
of the drug decreased, which could be related to the 
increased rigidity of the formulation, followed by its 
decreased permeability for the drug. Optimized formulation 
F4 shows significantly improved in drug release rate as 
compare to marketed preparation. It was concluded that 
developed formulations deliver the drug for the treatment of 
acne vulgaris table 5 and Fig 2. The kinetics of drug release 
from the optimized formulation (F4) was studied by 
mathematical modeling the drug release to zero order, first 
order kinetics Table 6 and Fig.3, 4. The antiacne activity of 
clindamycin emulgel (F4) was studied Table 7. The zone of 
inhibition was measure for antiacne activity of drug. The 
same activity was observed as compared to standard drug. 
 
Fig.1 Calibration curve of clindamycin phosphate in 
phosphate buffer pH 7.4 at 486nm
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Table 2 Physical parameter of formulation batches 
Formulation Colour Homogeneity Consistency Phase separation 
F1 White Excellent Excellent None 
F2 White Excellent Excellent None 
F3 White Excellent Excellent None 
F4 White Excellent Excellent None 
F5 White Excellent Excellent None 
F6 White Excellent Excellent None 
 
Table 3 Result of washability extrudability and spreadability study 
Formulation Washability Extrudability 
Spreadability 
(gcm/sec) 
F1 +++ ++ 12.25  
F2 +++ ++ 13.36 
F3 +++ +++ 14.56 
F4 +++ +++ 13.23 
F5 +++ ++ 14.56 
F6 +++ ++ 14.56 
Excellent: +++, Good: ++, Average: +, Poor: - 
Table 4 Viscosity and pH 
Formulation Viscosity (cps) pH 
F1 3280 7.05 
F2 3345 7.02 
F3 3280 6.95  
F4 3250 6.98 
F5 3352 7.05 
F6 3365 7.00 
 
Table 5 % Cum. drug release of formulation F1-F6 
  % Cum. drug release 
S. No. Time (min) F1 F2 F3 F4 F5 F6 Marketed 
1 0 0 0 0 0 0 0 0 
2 15 15.65 22.15 20.23 25.65 22.45 20.23 42.23 
3 30 26.65 32.25 33.12 36.65 38.89 35.65 65.56 
4 45 37.89 45.65 46.65 49.98 48.85 42.23 79.98 
5 60 46.65 52.25 53.32 57.89 53.32 50.32 94.46 
6 120 63.32 70.23 69.98 88.98 69.98 65.56 - 
7 240 76.65 74.56 76.65 98.89 82.23 75.56 - 
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15 3.873 0.588 25.65 1.409 74.35 1.871 
30 5.477 0.739 36.65 1.564 63.35 1.802 
45 6.708 0.827 49.98 1.699 50.02 1.699 
60 7.746 0.889 57.89 1.763 42.11 1.624 
120 10.954 1.040 88.98 1.949 11.02 1.042 
240 15.492 1.190 98.89 1.995 1.11 0.045 
* Average of three determinations 
 
Fig. 3 Graph of Zero order release kinetics of optimized formulation F4 
 
Fig. 4 Graph of First order release kinetics of optimized formulation F4 
Table 7 Antiacne activity of optimized emulgel F4 
S. No. Name of drug  Microbes Zone of inhibition  
10 μg/ml 20 μg/ml 30 μg/ml 
1. Clindamycin propionibacterium acne 26.5±0.1 29.5±0.2 33.5±0.2 
2 F4 propionibacterium acne 27.5±0.2 30.2±0.2 34.8±0.2 
 
CONCLUSION 
From the above results we can conclude that the clindamycin 
phosphate emulgel formulations prepared with carbopol-
941, light liquid paraffin, tween-20, span-20 and propylene 
glycol showed acceptable physical properties, drug release 
and anti acne activity, which remained unchanged upon 
storage for 3 months. However, the carbopol-941based 
emulgel in its low concentration with the formulation code 
F4 proved to be the formula of choice, since it showed the 
highest drug release and anti acne activity when compared 
to the marketed clindamycin gel. So, clindamycin phosphate 
emulgel can be used as anti acne medication for topical drug 
delivery. 
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